Pharmacokinetics of high-dose meropenem in adult cystic fibrosis patients

被引:27
作者
Bui, KQ
Ambrose, PG
Nicolau, DP
Lapin, CD
Nightingale, CH
Quintiliani, R
机构
[1] Hartford Hosp, Dept Med, Div Infect Dis, Hartford, CT 06102 USA
[2] Bristol Myers Squibb Co, Plainsboro, NJ USA
[3] Hartford Hosp, Dept Pharm Res, Hartford, CT 06102 USA
[4] Hartford Hosp, Off Res Adm, Hartford, CT 06102 USA
[5] Univ Connecticut, Ctr Hlth, Cyst Fibrosis Ctr, Hartford, CT 06112 USA
[6] Kendle Corp, Lawrenceville, NJ USA
关键词
D O I
10.1159/000063216
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Because patients with cystic fibrosis (CF) have pulmonary exacerbations secondary to multi-antibiotic-resistant Gram-negative bacilli, antibiotics, like meropenem, are often utilized. We studied the pharmacokinetics of meropenem (2 g i.v. administered every 8 h in clinically stable CF patients to determine if the recommended maximum doses could sustain adequate concentrations during the dosing interval. These pharmacokinetic data were similar to those obtained in non-CF populations. Using this regimen, concentrations of meropenem exceed the susceptibility breakpoint (4 mug/ml) for 50% of the dosing interval, and therefore provide optimization of the pharmacodynamic profile of the compound. Copyright (C) 2001 S. Karger AG, Basel.
引用
收藏
页码:153 / 156
页数:4
相关论文
共 17 条
[1]   PHARMACOKINETIC EVALUATION OF IMIPENEM COMBINED WITH CILASTATIN IN CYSTIC-FIBROSIS [J].
BERGAN, T ;
MICHALSEN, H ;
MALMBORG, AS ;
PEDERSEN, SS ;
PRESSLER, T ;
STORROSTEN, OT ;
STRANDVIK, B .
CHEMOTHERAPY, 1993, 39 (06) :369-373
[2]   Pharmacokinetics of meropenem in patients with cystic fibrosis [J].
Christensson, BA ;
Ljungberg, B ;
Eriksson, L ;
Nilsson-Ehle, I .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1998, 17 (12) :873-876
[3]   INTERRELATIONSHIP BETWEEN PHARMACOKINETICS AND PHARMACODYNAMICS IN DETERMINING DOSAGE REGIMENS FOR BROAD-SPECTRUM CEPHALOSPORINS [J].
CRAIG, WA .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1995, 22 (1-2) :89-96
[4]   The pharmacology of meropenem, a new carbapenem antibiotic [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 1997, 24 :S266-S275
[5]   PHARMACOKINETICS OF TICARCILLIN IN PATIENTS WITH CYSTIC-FIBROSIS - A CONTROLLED PROSPECTIVE-STUDY [J].
DEGROOT, R ;
HACK, BD ;
WEBER, A ;
CHAFFIN, D ;
RAMSEY, B ;
SMITH, AL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 47 (01) :73-78
[6]  
DRUSANO GL, 1995, SCAND J INFECT DIS, P11
[7]   High-performance liquid chromatographic assay for meropenem in serum [J].
Elkhaili, H ;
Niedergang, S ;
Pompei, D ;
Linger, L ;
Leveque, D ;
Jehl, F .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1996, 686 (01) :19-26
[8]  
JUSKO WJ, 1975, PEDIATRICS, V56, P1038
[9]  
LIETMAN PS, 1988, CHEST, V94, pS115
[10]   A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide [J].
Pfaller, MA ;
Jones, RN .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1997, 28 (04) :157-163